DiabetesNCT05259735
A Clinical Guideline-based Management of Type-2 Diabetes by Ayurvedic Practitioners in Nepal
A study testing Clinical Guideline based Management and Comparator in people with Diabetes and Type2Diabetes, run by Nepal Health Research Council at 1 site in Nepal.
Trial summary
T2DM is a complex disorder which has major health, social and economic consequences. Its chronic hyperglycaemia is associated with macro- and micro-vascular complications and even death. The prevalence of T2DM in Nepal is high. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes, Type2Diabetes, Diabetes Mellitus
- What is being tested?
- Clinical Guideline based Management and Comparator
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 121 participants
- Where
- 1 siteNepal
- Study dates
- 17 Jul 2022to 4 Jan 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- aged ≥18 years
- new T2DM patients (i.e., treatment naïve), diagnosed by the participating Ayurvedic practitioner
- able to provide written informed consent.
Who cannot join
- Pregnant women
- those with any serious or uncontrolled medical condition (e.g., cancer)
- those currently receiving (or has plans to receive during the study period) any related non-pharmaceutical/pharmaceutical intervention.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinical Guideline-based Management of Type-2 Diabetes by Ayurvedic Practitioners in Nepal: a Feasibility Cluster Randomised Controlled Trial
T2DM is a complex disorder which has major health, social and economic consequences. Its chronic hyperglycaemia is associated with macro- and micro-vascular complications and even death. The prevalence of T2DM in Nepal is high.
In Nepal, Ayurveda is the dominant traditional medical system and is in use for thousands of years, especially for meeting the primary healthcare needs. Lack of availability of western medical system doctors in rural areas is another reason. In recognition of these facts, the Nepalese government actively promotes Ayurveda and deploys Ayurvedic practitioners in PHCs, often as the main clinical provider.
Read more
This is a two-arm, feasibility cluster RCT with blinded outcome assessment and integrated qualitative process evaluation will be conducted in 12 Ayurvedic Primary Health Care Center Participants who are aged 18 years or above, new T2DM patients (i.e., treatment naïve), diagnosed by the participating Ayurvedic practitioner and able to provide written informed consent will be enrolled in the study. Each participant will be involved in the study for six months.
Patient will be assessed for Glycated haemoglobin, Lipid Profile, Physiological parameters like heart rate and pulse rate, Anthropometric parameters, EuroQol-5D-5L
Read the detailed description
In Nepal, Ayurveda is the dominant traditional medical system and is in use for thousands of years, especially for meeting the primary healthcare needs. The classical texts are written in Sanskrit, an ancient language. T2DM is one of the top diseases for which patients consult Ayurvedic practitioners, and many T2DM patients use Ayurvedic treatments, often from the beginning and exclusively and throughout their lives.Ayurveda fits their health beliefs and culture. Acceptability, satisfaction and perceived relief are usually high, especially among rural, poor, older and tribal populations. Many T2DM patients prefer not to use western medicines - to avoid the associated side-effects and costs and the mode of administration like insulin injections. Lack of availability of western medical system doctors in rural areas is another reason. In recognition of these facts, the Nepalese government actively promotes Ayurveda and deploys Ayurvedic practitioners in PHCs, often as the main clinical provider.
Strong concerns remain about the sub-optimal T2DM management of many patients, arising from the unacceptable variations in Ayurvedic clinical practice. The actions to be taken at different stages of the T2DM care pathway are largely left to the judgment of the individual Ayurvedic practitioner (including screening for complications and referral to specialists), resulting in these unacceptable variations. Despite the clinical effectiveness and safety of several Ayurvedic medicines for managing T2DM found in trial settings, many non-evidence based herbal and herbo-mineral medicines are prescribed by them in real practice, which can have serious adverse effects on patients, including heavy metal poisoning. It is exceedingly difficult for them to be versed with the latest data on most effective and safe Ayurvedic medicines. One of the major challenges identified by them in their clinical decision-making process and delivering quality care to T2DM patients is the absence of a good quality clinical guideline. Its absence forces many of them to blindly follow the claims made by others or use a 'trial and error' approach.
Faced with similar issues in the western medical system, clinical guidelines have been effectively deployed in every aspect of clinical care in the last few decades. For example, clinical trials conducted in English and Mexican primary care settings found that the introduction of clinical guidelines was effective in managing T2DM. Despite their pervasive use in the western medical system, their existence in Ayurvedic clinical practice remains extremely limited. Many stakeholders, including Ayurvedic practitioners, patient groups, the Nepalese government and WHO, are advocating for good quality clinical guidelines for Ayurvedic practitioners. Thus, a good quality clinical guideline, based on the best available evidence, to manage T2DM by Ayurvedic practitioners may address the problems mentioned above. We searched a range of trial registries and databases, and no study is investigating the utility of such an intervention for managing T2DM by Ayurvedic practitioners. Thus, there is a need for a robustly designed pragmatic study to evaluate such an innovative approach.
This is a two-arm, feasibility cluster RCT with blinded outcome assessment and integrated qualitative process evaluation.
12 Primary Health Centres (PHCs) with at least one Ayurvedic practitioner (most have only one) for the duration of the study and willing to participate in the study will be randomised (1:1) to intervention or comparator groups by an independent statistician according to a computer-generated randomisation schedule. PHCs should be screened for eligibility (PHC Screening and Randomisation Form) and recorded on the Screening of PHCs Eligible PHCs will be randomised and provided Site ID.
Ayurvedic practitioners and patients cannot be 'blinded' to group allocation, but the outcome assessor will be 'blind'.
- Conditions
- Diabetes, Type2Diabetes, Diabetes Mellitus
- Being tested
- Clinical Guideline based Management, Comparator
- Keywords
- Ayurveda, DiabetesMellitus, ClinicalGuideline
- Medical subject headings
- Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical Guideline based ManagementCombination product
Clinical guidline based management will be done for Type 2 diabetes Mellitus
ComparatorOther
In this arm usual management of T2DM without any clinical guideline
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Clinical guideline-based management of T2DM by Ayurvedic practitioners. The clinical guideline will cover topics like diagnostic criteria, blood glucose targets, lifestyle advice, Ayurvedic medicines, monitoring and follow-up (including screening for complications and referral to specialists for complications management). The clinical guideline will make recommendations based on the best available evidence. Ayurvedic practitioners will have at least a 5½ year undergraduate medical degree in Ayurveda. Regular training will be provided to Ayurvedic practitioners (in groups) in the use of clinical guideline which will involve roleplaying and structured and instructive feedback to improve their performance. The trainings will be recorded on the Training Attendance Log and they will be provided a Training Certificate for completing the training. Receives: Combination Product: Clinical Guideline based Management |
| Comparator | Active comparator | Comparator: Currently, no standard clinical guideline is used by Ayurvedic practitioners to manage T2DM in Nepal. Thus, the comparator will be the usual management of T2DM (i.e., without any clinical guideline) by Ayurvedic practitioners.
Participants will continue their medications for other systemic diseases, if any. Receives: Other: Comparator |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the change in the management of type-2 Diabetes with the introduction of Clinical Guideline
The assessment will be done in the baseline and the end line by measuring HbA1C
Measured: Assessment will be done from the data of screening until the 6 months
To assess the change Health related quality of life with the introduction of clinical guideline
Health related quality of life will be assessed in the baseline and the end line through HRQOL questionnaire
Measured: Assessment will be done from the data of screening until the 6 months
Secondary outcomes (2)
To determine the rate of dropout
To compare the rate of dropout in the intervention and control group ,
Measured: From the date of screening until the 6 months
To determine the number of participants who adhere to the guideline
To determine the rate of participants adhering to the guideline
Measured: From the date of screening until the 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2022
- Study start17 Jul 2022
- Primary completion4 Jan 2024
- Study completion4 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 121 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nepal Health Research Council
- Sponsor type
- Other government
- Collaborators
- University of Nottingham
- Responsible party
- Principal investigator, Dr. Pradip Gyanwali,MD, Nepal Health Research Council
- Investigators
- Kaushik Chattopadhyay, MPH, Principal investigator, University of NottinghamPradip Gyanwali, MD, Principal investigator, Nepal Health Research Council
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05259735
- Sponsor's protocol ID
- Ayurveda DM Study
- Status last verified
- Feb 2024
- First submitted
- 8 Feb 2022
- Last updated
- 22 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chattopadhyay K, Karki S, Wang H, Regmi P, Gyanwali P, Upadhyay V, Heinrich M, Bista B, Tandon N, Kinra S, Greenfield SM, Biswas TK, Jeemon P, Leonardi-Bee J, Lewis SA, Dhimal M. Diabetes Management by Ayurvedic Practitioners Using a Clinical Guideline Versus Usual Practice: A Feasibility Cluster Randomized Trial in Nepal. J Diabetes Res. 2026;2026(1):e2602864. doi: 10.1155/jdr/2602864.
PubMed 42057342
Study at a glance
From the registry record, last updated by the sponsor on 22 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Guideline-based Management of Type-2 Diabetes by Ayurvedic Practitioners in Nepal: a Feasibility Cluster Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT05259735
- Acronym / sponsor ID
- Ayurveda DM Study
- Conditions
- Diabetes, Type2Diabetes, Diabetes Mellitus
- Keywords
- Ayurveda, DiabetesMellitus, ClinicalGuideline
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 121 participants (actual)
- Lead sponsor
- Nepal Health Research CouncilOther government
- Collaborators
- University of Nottingham
- Study start
- 17 Jul 2022 (actual)
- Primary completion
- 4 Jan 2024 (actual)
- Study completion
- 4 Jan 2024 (actual)
- First posted
- 2 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
T2DM is a complex disorder which has major health, social and economic consequences. Its chronic hyperglycaemia is associated with macro- and micro-vascular complications and even death. The prevalence of T2DM in Nepal is high.
In Nepal, Ayurveda is the dominant traditional medical system and is in use for thousands of years, especially for meeting the primary healthcare needs. Lack of availability of western medical system doctors in rural areas is another reason. In recognition of these facts, the Nepalese government actively promotes Ayurveda and deploys Ayurvedic practitioners in PHCs, often as the main clinical provider.
This is a two-arm, feasibility cluster RCT with blinded outcome assessment and integrated qualitative process evaluation will be conducted in 12 Ayurvedic Primary Health Care Center Participants who are aged 18 years or above, new T2DM patients (i.e., treatment naïve), diagnosed by the participating Ayurvedic practitioner and able to provide written informed consent will be enrolled in the study. Each participant will be involved in the study for six months.
Patient will be assessed for Glycated haemoglobin, Lipid Profile, Physiological parameters like heart rate and pulse rate, Anthropometric parameters, EuroQol-5D-5L
Detailed description
In Nepal, Ayurveda is the dominant traditional medical system and is in use for thousands of years, especially for meeting the primary healthcare needs. The classical texts are written in Sanskrit, an ancient language. T2DM is one of the top diseases for which patients consult Ayurvedic practitioners, and many T2DM patients use Ayurvedic treatments, often from the beginning and exclusively and throughout their lives.Ayurveda fits their health beliefs and culture. Acceptability, satisfaction and perceived relief are usually high, especially among rural, poor, older and tribal populations. Many T2DM patients prefer not to use western medicines - to avoid the associated side-effects and costs and the mode of administration like insulin injections. Lack of availability of western medical system doctors in rural areas is another reason. In recognition of these facts, the Nepalese government actively promotes Ayurveda and deploys Ayurvedic practitioners in PHCs, often as the main clinical provider.
Strong concerns remain about the sub-optimal T2DM management of many patients, arising from the unacceptable variations in Ayurvedic clinical practice. The actions to be taken at different stages of the T2DM care pathway are largely left to the judgment of the individual Ayurvedic practitioner (including screening for complications and referral to specialists), resulting in these unacceptable variations. Despite the clinical effectiveness and safety of several Ayurvedic medicines for managing T2DM found in trial settings, many non-evidence based herbal and herbo-mineral medicines are prescribed by them in real practice, which can have serious adverse effects on patients, including heavy metal poisoning. It is exceedingly difficult for them to be versed with the latest data on most effective and safe Ayurvedic medicines. One of the major challenges identified by them in their clinical decision-making process and delivering quality care to T2DM patients is the absence of a good quality clinical guideline. Its absence forces many of them to blindly follow the claims made by others or use a 'trial and error' approach.
Faced with similar issues in the western medical system, clinical guidelines have been effectively deployed in every aspect of clinical care in the last few decades. For example, clinical trials conducted in English and Mexican primary care settings found that the introduction of clinical guidelines was effective in managing T2DM. Despite their pervasive use in the western medical system, their existence in Ayurvedic clinical practice remains extremely limited. Many stakeholders, including Ayurvedic practitioners, patient groups, the Nepalese government and WHO, are advocating for good quality clinical guidelines for Ayurvedic practitioners. Thus, a good quality clinical guideline, based on the best available evidence, to manage T2DM by Ayurvedic practitioners may address the problems mentioned above. We searched a range of trial registries and databases, and no study is investigating the utility of such an intervention for managing T2DM by Ayurvedic practitioners. Thus, there is a need for a robustly designed pragmatic study to evaluate such an innovative approach.
This is a two-arm, feasibility cluster RCT with blinded outcome assessment and integrated qualitative process evaluation.
12 Primary Health Centres (PHCs) with at least one Ayurvedic practitioner (most have only one) for the duration of the study and willing to participate in the study will be randomised (1:1) to intervention or comparator groups by an independent statistician according to a computer-generated randomisation schedule. PHCs should be screened for eligibility (PHC Screening and Randomisation Form) and recorded on the Screening of PHCs Eligible PHCs will be randomised and provided Site ID.
Ayurvedic practitioners and patients cannot be 'blinded' to group allocation, but the outcome assessor will be 'blind'.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Combination Product: Clinical Guideline based ManagementClinical guideline-based management of T2DM by Ayurvedic practitioners. The clinical guideline will cover topics like diagnostic criteria, blood glucose targets, lifestyle advice, Ayurvedic medicines, monitoring and follow-up (including screening for complications and referral to specialists for complications management). The clinical guideline will make recommendations based on the best available evidence. Ayurvedic practitioners will have at least a 5½ year undergraduate medical degree in Ayurveda. Regular training will be provided to Ayurvedic practitioners (in groups) in the use of clinical guideline which will involve roleplaying and structured and instructive feedback to improve their performance. The trainings will be recorded on the Training Attendance Log and they will be provided a Training Certificate for completing the training. |
| Comparator | Active comparator | Other: ComparatorComparator: Currently, no standard clinical guideline is used by Ayurvedic practitioners to manage T2DM in Nepal. Thus, the comparator will be the usual management of T2DM (i.e., without any clinical guideline) by Ayurvedic practitioners. Participants will continue their medications for other systemic diseases, if any. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- aged ≥18 years
- new T2DM patients (i.e., treatment naïve), diagnosed by the participating Ayurvedic practitioner
- able to provide written informed consent.
Key exclusion criteria (3 listed)
- Pregnant women
- those with any serious or uncontrolled medical condition (e.g., cancer)
- those currently receiving (or has plans to receive during the study period) any related non-pharmaceutical/pharmaceutical intervention.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical Guideline based ManagementClinical guidline based management will be done for Type 2 diabetes Mellitus | Combination product | Intervention |
| ComparatorIn this arm usual management of T2DM without any clinical guideline | Other | Comparator |
Primary outcome
To assess the change in the management of type-2 Diabetes with the introduction of Clinical Guideline
Time frame: Assessment will be done from the data of screening until the 6 months
The assessment will be done in the baseline and the end line by measuring HbA1C
To assess the change Health related quality of life with the introduction of clinical guideline
Time frame: Assessment will be done from the data of screening until the 6 months
Health related quality of life will be assessed in the baseline and the end line through HRQOL questionnaire
2 secondary outcomes
To determine the rate of dropout
Time frame: From the date of screening until the 6 months
To determine the number of participants who adhere to the guideline
Time frame: From the date of screening until the 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Feb 2024.
- Derived from this study: PubMed 42057342Chattopadhyay K, Karki S, Wang H, Regmi P, Gyanwali P, Upadhyay V, Heinrich M, Bista B, Tandon N, Kinra S, Greenfield SM, Biswas TK, Jeemon P, Leonardi-Bee J, Lewis SA, Dhimal M. Diabetes Management by Ayurvedic Practitioners Using a Clinical Guideline Versus Usual Practice: A Feasibility Cluster Randomized Trial in Nepal. J Diabetes Res. 2026;2026(1):e2602864. doi: 10.1155/jdr/2602864.
- Individual participant dataSharing planned: No
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kaushik Chattopadhyay, MPH principal investigator
University of Nottingham
Pradip Gyanwali, MD principal investigator
Nepal Health Research Council
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinical Guideline based Management and Comparator in people with Diabetes and Type2Diabetes, run by Nepal Health Research Council at 1 site in Nepal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the change in the management of type-2 Diabetes with the introduction of Clinical Guideline (time frame: Assessment will be done from the data of screening until the 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05259735, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2024.